Journal
BJU INTERNATIONAL
Volume 104, Issue 6, Pages 867-873Publisher
WILEY
DOI: 10.1111/j.1464-410X.2009.08549.x
Keywords
bacille Calmette-Guerin; polymerase chain reaction (PCR); polymorphism; recurrence; TNF-alpha; bladder cancer
Categories
Funding
- Department of Science and Technology, New Delhi, India
- Department of Biotechnology, New Delhi, India
- Indian Council of Medical Research, New Delhi, India
Ask authors/readers for more resources
OBJECTIVE To investigate the association of tumour necrosis factor-alpha gene (TNF-alpha) polymorphisms T-1031C, C-863A, and C-857T with bladder cancer risk and recurrence after bacille Calmette-Guerin (BCG) immunotherapy, as TNF-alpha regulates inflammatory process influencing bladder cancer susceptibility and outcome of BCG immunotherapy. PATIENTS AND METHODS In all, 220 patients with bladder cancer and 206 controls were recruited. Genotyping was done using allele specific-polymerase chain reaction. RESULTS A T-1031C, CC genotype and haplotype -1031C/-863C/-857T showed enhanced susceptibility to bladder cancer, with an odds ratio (OR) of 2.23 and 95% confidence interval (CI) of 1.17-4.26; and an OR of 6.05 and 95%CI of 2.46-14.90, respectively. A T-1031C, CC genotype had a reduced risk of recurrence after BCG treatment (hazard ratio 0.38, 95%CI 0.14-0.98). CONCLUSION The present data suggests that T-1031C (CC) genotype and C/C/T haplotype may confer risk for bladder cancer, moreover T-1031C (CC) decreased the risk of recurrence after BCG immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available